Eli Lilly Management
Management criteria checks 2/4
Eli Lilly's CEO is Dave Ricks, appointed in Jan 2017, has a tenure of 7.33 years. total yearly compensation is $26.57M, comprised of 6.1% salary and 93.9% bonuses, including company stock and options. directly owns 0.076% of the company’s shares, worth $534.48M. The average tenure of the management team and the board of directors is 5.9 years and 9.5 years respectively.
Key information
Dave Ricks
Chief executive officer
US$26.6m
Total compensation
| CEO salary percentage | 6.1% |
| CEO tenure | 7.3yrs |
| CEO ownership | 0.08% |
| Management average tenure | 5.9yrs |
| Board average tenure | 9.5yrs |
Recent management updates
Recent updates
Eli Lilly: Bloated Stock
May 01What You Can Learn From Eli Lilly and Company's (NYSE:LLY) P/S
Apr 22
Wall Street Lunch: Lilly In Limelight
Apr 17Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets
Mar 29Eli Lilly: The Party Is Not Over
Mar 23Estimating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)
Mar 17Eli Lilly: Yes, It Is Too Late To Join The Party
Feb 20Eli Lilly: Overvaluation Is A Big Red Flag
Feb 14Eli Lilly and Company: Even 'Miracle Drugs' Can't Keep Stock Rising (Downgrade)
Feb 07Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value
Jan 31Eli Lilly (NYSE:LLY) Has Announced That It Will Be Increasing Its Dividend To $1.30
Jan 24Eli Lilly: The Cupboard Is Fully Stocked
Jan 19Eli Lilly: The Buzz Is Not Over
Jan 11Eli Lilly (NYSE:LLY) Is Increasing Its Dividend To $1.30
Jan 10Eli Lilly (NYSE:LLY) Is Paying Out A Larger Dividend Than Last Year
Dec 27Pinning Down Eli Lilly and Company's (NYSE:LLY) P/S Is Difficult Right Now
Dec 24Eli Lilly: Long Path To A Trillion
Dec 21Eli Lilly (NYSE:LLY) Has A Pretty Healthy Balance Sheet
Dec 05Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly
Nov 30Eli Lilly: Perfectly Priced Healthcare Giant
Nov 16Eli Lilly: Zepbound For Weight Loss FDA Approved - Time To Believe The Hype?
Nov 09Calculating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)
Oct 30Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated
Oct 11Eli Lilly: Big Cancer Bet With Point Biopharma Global Purchase
Oct 05Eli Lilly: Don't Be Fooled By Greed
Sep 20Eli Lilly Stock Hits New All-Time Highs: Is It Still A Buy?
Sep 11Here's Why We Think Eli Lilly (NYSE:LLY) Is Well Worth Watching
Sep 11Is Eli Lilly (NYSE:LLY) Using Too Much Debt?
Aug 24Sell Eli Lilly And Buy This Coiled-Spring Dividend Aristocrat Instead
Aug 23CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$27m | US$2m | US$5b |
| Sep 30 2023 | n/a | n/a | US$5b |
| Jun 30 2023 | n/a | n/a | US$6b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$21m | US$2m | US$6b |
| Sep 30 2022 | n/a | n/a | US$6b |
| Jun 30 2022 | n/a | n/a | US$6b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$22m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$6b |
| Dec 31 2020 | US$24m | US$1m | US$6b |
| Sep 30 2020 | n/a | n/a | US$6b |
| Jun 30 2020 | n/a | n/a | US$6b |
| Mar 31 2020 | n/a | n/a | US$6b |
| Dec 31 2019 | US$21m | US$1m | US$5b |
| Sep 30 2019 | n/a | n/a | US$4b |
| Jun 30 2019 | n/a | n/a | US$4b |
| Mar 31 2019 | n/a | n/a | US$3b |
| Dec 31 2018 | US$17m | US$1m | US$3b |
| Sep 30 2018 | n/a | n/a | US$372m |
| Jun 30 2018 | n/a | n/a | -US$166m |
| Mar 31 2018 | n/a | n/a | US$1b |
| Dec 31 2017 | US$16m | US$1m | -US$86m |
Compensation vs Market: Dave's total compensation ($USD26.57M) is above average for companies of similar size in the US market ($USD13.62M).
Compensation vs Earnings: Dave's compensation has increased by more than 20% in the past year.
CEO
Dave Ricks (55 yo)
7.3yrs
Tenure
US$26,565,732
Compensation
Mr. David A. Ricks, also known as Dave, has been a Director of Adobe Inc. since April 12, 2018 and previously served as its Director since June 2017. He served as a Director of Elanco Animal Health Incorpo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 7.3yrs | US$26.57m | 0.076% $ 534.5m | |
| Executive VP & CFO | 3.3yrs | US$7.60m | 0.0047% $ 33.1m | |
| EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology | 5.9yrs | US$11.85m | 0.022% $ 150.7m | |
| Executive VP | 4.3yrs | US$7.01m | 0.0034% $ 23.7m | |
| Executive VP & President of Loxo | no data | US$4.89m | 0.0023% $ 16.0m | |
| Senior VP of Finance & Chief Accounting Officer | 11.5yrs | no data | 0.0011% $ 7.5m | |
| EVP & Chief Information and Digital Officer | 3yrs | US$5.10m | 0.00087% $ 6.1m | |
| EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer | 2.9yrs | no data | 0.00088% $ 6.2m | |
| Executive Vice President of Human Resources & Diversity | 1.4yrs | no data | 0.00083% $ 5.8m | |
| Senior VP & President of Elanco Animal Health | 16.3yrs | US$5.38m | no data | |
| SVP of Global Active Pharmaceutical Ingredient | 7.8yrs | no data | no data | |
| Executive Vice President of Global Quality | 7.1yrs | no data | 0.0039% $ 27.0m |
5.9yrs
Average Tenure
52.5yo
Average Age
Experienced Management: LLY's management team is seasoned and experienced (5.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 7.3yrs | US$26.57m | 0.076% $ 534.5m | |
| Independent Director | 3.3yrs | US$335.50k | no data | |
| Chairman Emeritus | 15.3yrs | US$13.06m | no data | |
| Independent Director | 18.5yrs | US$344.88k | 0.000010% $ 70.0k | |
| Independent Director | 15.1yrs | US$336.00k | 0.000080% $ 560.2k | |
| Independent Director | 11.9yrs | US$349.15k | no data | |
| Lead Independent Director | 8.3yrs | US$373.00k | no data | |
| Independent Director | 12.4yrs | US$336.00k | no data | |
| Independent Director | 7.6yrs | US$345.00k | no data | |
| Independent Director | 10.7yrs | US$319.00k | 0.000020% $ 140.1k | |
| Independent Director | 5.4yrs | US$359.00k | no data | |
| Independent Director | 3.3yrs | US$316.00k | no data |
9.5yrs
Average Tenure
62.5yo
Average Age
Experienced Board: LLY's board of directors are considered experienced (9.5 years average tenure).